Improving Clinical Outcomes, Expanded Services, Earnings Schedule and Guidance - Research Report on Abbott, Baxter, PerkinElmer, Allscripts and Parexel Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, July 10, 2013 NEW YORK, July 10, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Baxter International Inc. (NYSE: BAX), PerkinElmer Inc. (NYSE: PKI), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) and PAREXEL International Corporation (NASDAQ: PRXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Abbott LaboratoriesResearch Report On June 20, 2013, Abbott Laboratories (Abbott) introduced the first FDA-approved hepatitis C virus (HCV) genotyping test for patients in the U.S., which provides physicians with important information they can use to create a personalized, targeted diagnosis and treatment path to improve clinical outcomes. "The Abbott RealTime HCV Genotype II test adds yet another test to the Abbott portfolio for a full spectrum of hepatitis C testing from ensuring blood supply safety and providing initial screening to enabling targeted diagnoses, identification of the right treatments, and the monitoring of response to therapies," said John Coulter, Vice President, Molecular Diagnostics, Abbott. "Abbott continues to expand diagnostic testing options in the infectious disease area to benefit the healthcare system and enable doctors to improve patient care." The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0bcf_ABT] -- Baxter International Inc.Research Report On July 5, 2013, Baxter International Inc. (Baxter) presented ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] data on Prophylaxis Management and Efficacy for Hemophilia A, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam. According to Baxter, the first study identifies a correlation between peak levels of factor VIII in the body and the efficacy of treatment, indicating that frequency of peaks may be important when choosing hemophilia treatments. A second presentation suggested that for both hemophilia patients and parents, efficacy through reduction in bleeds considerably outweighs infusion convenience as the primary treatment priority. "Overall, these studies emphasize that with regard to hemophilia patient care regimens, treatment is simply not a 'one size fits all' approach, and individualized regimens can help optimize the effectiveness each patient achieves," said Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development in Baxter's BioScience business. "Meeting the needs of individual patients and raising the standard of care are the primary focus of Baxter's long-term commitment in hemophilia and our pursuit of a future where one day, every patient can live a life without bleeds." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/103a_BAX] -- PerkinElmer Inc.Research Report On July 5, 2013, PerkinElmer Inc. (PerkinElmer) announced its earnings call schedule. The Company will release its Q2 2013 results on Thursday, August 1, 2013, after the market close. Following the release of the results, the Company will host a conference call on the same day at 5:00 p.m. ET. Robert F. Friel, the Company's Chairman and Chief Executive Officer will host the conference call together with, Andy Wilson, Senior Vice President and Chief Financial Officer. A live audio webcast of the call will also be available on the investor section of the Company's Web site. Further, on June 13, 2013, the Company's Board of Directors had declared a quarterly dividend of $0.07 per share of common stock, payable on August 9, 2013, to all shareholders of record at the close of business on July 19, 2013. The Full Research Report on PerkinElmer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2d16_PKI] -- Allscripts Healthcare Solutions, Inc.Research Report On July 1, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) and Liberty Hospital announced an agreement for Allscripts to manage Liberty Hospital's information technology (IT) services. "Allscripts is a global company that has deep IT expertise," commented David Feess, President and Chief Executive Officer of Liberty Hospital. "By combining our team with theirs, we will be able to put long-term strategies and systems in place that will last far into our future." Liberty Hospital currently has 30 employees managing the computer information systems and IT programs at the hospital, clinics and affiliates, and with the new agreement, these employees will transfer to the Allscripts staff and be managed by Kelly Dungee, Liberty Hospital Interim Chief Information Officer. The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1d85_MDRX] -- PAREXEL International CorporationResearch Report On June 25, 2013, PAREXEL International Corp. (Parexel) announced its earnings expectations for Q4 FY 2013, full-year FY 2013 and full-year FY 2014. The Company reaffirmed its guidance for Q4 FY 2013, anticipating consolidated service revenue in the range of $449 to $459 million and GAAP diluted EPS of $0.40 to $0.44. For full-year FY 2013, the Company continues to expect consolidated service revenue to be in the range of $1,720 to $1,730 million, and GAAP earnings per diluted share to be between $1.51 to $1.55, and adjusted earnings per diluted share to be in the range of $1.60 to $1.64. Further, the Company issued guidance estimates for FY 2014, anticipating consolidated service revenue in the range of $1,885 to $1,915 million, and GAAP earnings per diluted share between $1.90 and $2.10. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/037f_PRXL] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Improving Clinical Outcomes, Expanded Services, Earnings Schedule and Guidance - Research Report on Abbott, Baxter, PerkinElmer,
Press spacebar to pause and continue. Press esc to stop.